Drugs /

gsk3145095

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for gsk3145095

Gsk3145095 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating gsk3145095, 1 is phase 2 (0 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for gsk3145095 clinical trials.

Breast carcinoma, melanoma, and non-small cell lung carcinoma are the most common diseases being investigated in gsk3145095 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Gsk3145095
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gsk3145095 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ripk1 inhibitor gsk3145095
Drug Categories [2]:
Serine/threonine kinase inhibitors
Drug Target(s) [2]:
RIPK1

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.